Aya Kita
Overview
Explore the profile of Aya Kita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
760
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hojo M, Kita A, Kageyama R, Hashimoto N
Expert Rev Endocrinol Metab
. 2019 Feb;
3(1):91-100.
PMID: 30743788
The pituitary gland is a critical endocrine organ that controls homeostasis, metabolism, reproduction and growth. Pituitary organogenesis involves the initial proliferation process of progenitor cells and the subsequent differentiation process...
2.
Ando M, Goto M, Hojo M, Kita A, Kitagawa M, Ohtsuka T, et al.
J Mol Endocrinol
. 2018 Oct;
61(3):127-138.
PMID: 30307165
Multiple signaling molecules and transcription factors are required for pituitary development. Activator-type bHLH genes Mash1, Math, NeuroD (Neurod) and Neurogenin (Neurog) are well known as key molecules in neural development....
3.
Mitsuoka K, Kita A, Murakami Y, Shirasuna K, Noda A, Yamanaka K, et al.
Nucl Med Biol
. 2018 Jul;
64-65:41-46.
PMID: 30041149
Introduction: Sepantronium bromide (YM155) is a survivin suppressant that induces apoptosis in tumor cells. Although YM155 induces tumor regression in various tumor types in vivo, phase I and II studies...
4.
Goto M, Hojo M, Ando M, Kita A, Kitagawa M, Ohtsuka T, et al.
Brain Res
. 2015 Sep;
1625:206-17.
PMID: 26348989
The pituitary gland is a critical endocrine organ regulating diverse physiological functions, including homeostasis, metabolism, reproduction, and growth. It is composed of two distinct entities: the adenohypophysis, including the anterior...
5.
Shakushiro K, Kawano H, Nakata M, Kita A, Maeda A, Watanabe S, et al.
Pharm Res
. 2014 Jul;
32(1):238-47.
PMID: 25033765
Purpose: Sepantronium bromide (YM155) is administered by 168-hour continuous infusions in clinical studies due to its time-dependent pharmacological efficacy and rapid elimination from plasma. To enable more convenient administration, i.e.,...
6.
Kawano H, Shakushiro K, Nakata M, Kita A, Maeda A, Watanabe S, et al.
Eur J Pharm Biopharm
. 2014 Jul;
88(1):283-9.
PMID: 24993306
Sepantronium bromide (YM155) exhibits time-dependent antitumor activity, although the plasma half-life of YM155 after a bolus intravenous (i.v.) administration is very short. Therefore, greater antitumor efficacy is obtained by continuous...
7.
Kaneko N, Mitsuoka K, Amino N, Yamanaka K, Kita A, Mori M, et al.
Clin Cancer Res
. 2014 Feb;
20(7):1814-22.
PMID: 24486595
Purpose: There remains an unmet therapeutic need for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to evaluate the therapeutic potential of sepantronium bromide...
8.
Kaneko N, Yamanaka K, Kita A, Tabata K, Akabane T, Mori M
Biol Pharm Bull
. 2014 Jan;
36(12):1921-7.
PMID: 24432379
Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes, and effective treatment options are limited to cytotoxic agents, including microtubule-targeting agents, due to the lack of molecular...
9.
Kaneko N, Kita A, Yamanaka K, Mori M
Leuk Res
. 2013 Jun;
37(9):1156-61.
PMID: 23746965
Survivin and STAT3 pathway have been reported to be important for the growth of diffuse large B-cell lymphoma (DLBCL) cells. Here we investigated the antitumor activity of sepantronium bromide (YM155),...
10.
Murakami Y, Matsuya T, Kita A, Yamanaka K, Noda A, Mitsuoka K, et al.
Nucl Med Biol
. 2012 Nov;
40(2):221-6.
PMID: 23141550
Introduction: Sepantronium bromide (YM155) is an antitumor drug in development and is a first-in-class chemical entity, which is a survivin suppressant. We developed a radiosynthesis of [(11)C]YM155 to non-invasively evaluate...